Vaccines against respiratory viral pathogens for use in neonates: Opportunities and challenges

Journal of Immunology

Volumn 193, Issue 11, 2014, Pages 5363-5369

  Alexander Miller, Martha A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; FLAGELLIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; MIFAMURTIDE; PHOSPHORYL LIPID A; PROTEIN KINASE ZAP 70; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY AFFINITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; DENDRITIC CELL; DISEASE SEVERITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LOWER RESPIRATORY TRACT INFECTION; MORBIDITY; MORTALITY; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY VIRUS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION; ANIMAL; IMMUNOLOGY; NEWBORN; RESPIRATORY TRACT INFECTIONS; VIRUS; VIRUS DISEASES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; HUMANS; INFANT, NEWBORN; RESPIRATORY TRACT INFECTIONS; VACCINATION; VIRAL VACCINES; VIRUS DISEASES; VIRUSES;

EID: 84912553553     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401410     Document Type: Article

References (93)

1. Tregoning, J. S., and J. Schwarze. 2010. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. 23: 74-98.
2. Nair, H., E. A. Simões, I. Rudan, B. D. Gessner, E. Azziz-Baumgartner, J. S. Zhang, D. R. Feikin, G. A. Mackenzie, J. C. Moïsi, A. Roca, et al; Severe Acute Lower Respiratory Infections Working Group. 2013. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 381: 1380-1390.
3. Marr, N., T. I. Wang, S. H. Kam, Y. S. Hu, A. A. Sharma, A. Lam, J. Markowski, A. Solimano, P. M. Lavoie, and S. E. Turvey. 2014. Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. J. Immunol. 192: 948-957.
4. Adkins, B., C. Leclerc, and S. Marshall-Clarke. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4: 553-564.
5. Zaghouani, H., C. M. Hoeman, and B. Adkins. 2009. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol. 30: 585-591.
6. Ghazal, P., P. Dickinson, and C. L. Smith. 2013. Early life response to infection. Curr. Opin. Infect. Dis. 26: 213-218.
7. Cuenca, A. G., J. L. Wynn, L. L. Moldawer, and O. Levy. 2013. Role of innate immunity in neonatal infection. Am. J. Perinatol. 30: 105-112.
8. Roux, X., A. Remot, A. Petit-Camurdan, M. A. Nahori, H. Kiefer-Biasizzo, G. Marchal, M. Lagranderie, and S. Riffault. 2011. Neonatal lung immune responses show a shift of cytokines and transcription factors toward Th2 and a deficit in conventional and plasmacytoid dendritic cells. Eur. J. Immunol. 41: 2852-2861.
9. Willems, F., S. Vollstedt, and M. Suter. 2009. Phenotype and function of neonatal DC. Eur. J. Immunol. 39: 26-35.
10. Philbin, V. J., andO. Levy. 2009. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr. Res. 65: 98R-105R.
11. Kollmann, T. R., J. Crabtree, A. Rein-Weston, D. Blimkie, F. Thommai, X. Y. Wang, P. M. Lavoie, J. Furlong, E. S. Fortuno, III, A. M. Hajjar, et al. 2009. Neonatal innate TLR-mediated responses are distinct from those of adults. J. Immunol. 183: 7150-7160.
12. Philbin, V. J., D. J. Dowling, L. C. Gallington, G. Cortes, Z. Tan, E. E. Suter, K. W. Chi, A. Shuckett, L. Stoler-Barak, M. Tomai, R. L. Miller, K. Mansfield, and O. Levy. 2012. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J. Allergy Clin. Immunol. 130: 195-204.e9.
13. De Wit, D., S. Tonon, V. Olislagers, S. Goriely, M. Boutriaux, M. Goldman, and F. Willems. 2003. Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J. Autoimmun. 21: 277-281.
14. Harris, D. T., M. J. Schumacher, J. Locascio, F. J. Besencon, G. B. Olson, D. DeLuca, L. Shenker, J. Bard, and E. A. Boyse. 1992. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc. Natl. Acad. Sci. USA 89: 10006-10010.
15. Chen, L., A. C. Cohen, and D. B. Lewis. 2006. Impaired allogeneic activation and T-helper 1 differentiation of human cord blood naive CD4 T cells. Biol. Blood Marrow Transplant. 12: 160-171.
16. Nonoyama, S., L. A. Penix, C. P. Edwards, D. B. Lewis, S. Ito, A. Aruffo, C. B. Wilson, and H. D. Ochs. 1995. Diminished expression of CD40 ligand by activated neonatal T cells. J. Clin. Invest. 95: 66-75.
17. Miscia, S., A. Di Baldassarre, G. Sabatino, E. Bonvini, R. A. Rana, M. Vitale, V. Di Valerio, and F. A. Manzoli. 1999. Inefficient phospholipase C activation and reduced Lck expression characterize the signaling defect of umbilical cord T lymphocytes. J. Immunol. 163: 2416-2424.
18. Palin, A. C., V. Ramachandran, S. Acharya, and D. B. Lewis. 2013. Human neonatal naive CD4+ T cells have enhanced activation-dependent signaling regulated by the microRNA miR-181a. J. Immunol. 190: 2682-2691.
19. Evans, I. A., and C. A. Jones. 2005. HSV induces an early primary Th1 CD4 T cell response in neonatal mice, but reduced CTL activity at the time of the peak adult response. Eur. J. Immunol. 35: 1454-1462.
20. Fernandez, M. A., I. A. Evans, E. H. Hassan, F. R. Carbone, and C. A. Jones. 2008. Neonatal CD8+ T cells are slow to develop into lytic effectors after HSV infection in vivo. Eur. J. Immunol. 38: 102-113.
21. Crowe, J. E., Jr., and J. V. Williams. 2003. Immunology of viral respiratory tract infection in infancy. Paediatr. Respir. Rev. 4: 112-119.
22. Randolph, D. A. 2005. The neonatal adaptive immune system. NeoReviews 6: e454-e462.
23. Brandenburg, A. H., J. Groen, H. A. van Steensel-Moll, E. C. Claas, P. H. Rothbarth, H. J. Neijens, and A. D. Osterhaus. 1997. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J. Med. Virol. 52: 97-104.
24. Tregoning, J. S., B. L. Wang, J. U. McDonald, Y. Yamaguchi, J. A. Harker, M. Goritzka, C. Johansson, A. Bukreyev, P. L. Collins, and P. J. Openshaw. 2013. Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection. Proc. Natl. Acad. Sci. USA 110: 5576-5581.
25. Debock, I., K. Jaworski, H. Chadlaoui, S. Delbauve, N. Passon, L. Twyffels, O. Leo, and V. Flamand. 2013. Neonatal follicular Th cell responses are impaired and modulated by IL-4. J. Immunol. 191: 1231-1239.
26. Pihlgren, M., C. Tougne, P. Bozzotti, A. Fulurija, M. A. Duchosal, P. H. Lambert, and C. A. Siegrist. 2003. Unresponsiveness to lymphoid-mediated signals at the neonatal follicular dendritic cell precursor level contributes to delayed germinal center induction and limitations of neonatal antibody responses to T-dependent antigens. J. Immunol. 170: 2824-2832.
27. Siegrist, C. A. 2007. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol. 137(Suppl. 1): S4-S9.
28. Kaur, K., S. Chowdhury, N. S. Greenspan, and J. R. Schreiber. 2007. Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates. Blood 110: 2948-2954.
29. Vincent, F. B., D. Saulep-Easton, W. A. Figgett, K. A. Fairfax, and F. Mackay. 2013. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24: 203-215.
30. Rickert, R. C., J. Jellusova, and A. V. Miletic. 2011. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol. Rev. 244: 115-133.
31. Belnoue, E., M. Pihlgren, T. L. McGaha, C. Tougne, A. F. Rochat, C. Bossen, P. Schneider, B. Huard, P. H. Lambert, and C. A. Siegrist. 2008. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111: 2755-2764.
32. Wolf, A. I., K. Mozdzanowska, W. J. Quinn, III, M. Metzgar, K. L. Williams, A. J. Caton, E. Meffre, R. J. Bram, L. D. Erickson, D. Allman, et al. 2011. Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI. J. Clin. Invest. 121: 3954-3964.
33. Halista, S. M., L. A. Johnson-Robbins, A. E. El-Mohandes, A. Lees, J. J. Mond, and I. M. Katona. 1998. Characterization of early activation events in cord blood B cells after stimulation with T cell-independent activators. Pediatr. Res. 43: 496-503.
34. Groothuis, J. R., M. J. Levin, G. P. Rabalais, G. Meiklejohn, and B. A. Lauer. 1991. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics 87: 823-828.
35. Halasa, N. B., M. A. Gerber, Q. Chen, P. F. Wright, and K. M. Edwards. 2008. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J. Infect. Dis. 197: 1448-1454.
36. Neuzil, K. M., W. D. Dupont, P. F. Wright, and K. M. Edwards. 2001. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr. Infect. Dis. J. 20: 733-740.
37. Gans, H., R. DeHovitz, B. Forghani, J. Beeler, Y. Maldonado, and A. M. Arvin. 2003. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 21: 3398-3405.
38. Vekemans, J., M. O. Ota, E. C. Wang, M. Kidd, L. K. Borysiewicz, H. Whittle, K. P. McAdam, G. Morgan, and A. Marchant. 2002. T cell responses to vaccines in infants: defective IFNgamma production after oral polio vaccination. Clin. Exp. Immunol. 127: 495-498.
39. Vekemans, J., A. Amedei, M. O. Ota, M. M. D'Elios, T. Goetghebuer, J. Ismaili, M. J. Newport, G. Del Prete, M. Goldman, K. P. McAdam, and A. Marchant. 2001. Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur. J. Immunol. 31: 1531-1535.
40. Moyron-Quiroz, J. E., J. Rangel-Moreno, K. Kusser, L. Hartson, F. Sprague, S. Goodrich, D. L. Woodland, F. E. Lund, and T. D. Randall. 2004. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10: 927-934.
41. Richert, L. E., A. L. Harmsen, A. Rynda-Apple, J. A. Wiley, A. E. Servid, T. Douglas, and A. G. Harmsen. 2013. Inducible bronchus-associated lymphoid tissue (iBALT) synergizes with local lymph nodes during antiviral CD4+ T cell responses. Lymphat. Res. Biol. 11: 196-202.
42. Norton, E. B., J. D. Clements, T. G. Voss, and L. Cárdenas-Freytag. 2010. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J. Virol. 84: 2983-2995.
43. Rangel-Moreno, J., D. M. Carragher, M. de la Luz Garcia-Hernandez, J. Y. Hwang, K. Kusser, L. Hartson, J. K. Kolls, S. A. Khader, and T. D. Randall. 2011. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12: 639-646.
44. Hussell, T., and T. J. Bell. 2014. Alveolar macrophages: plasticity in a tissue-specific context. Nat. Rev. Immunol. 14: 81-93.
45. Slütter, B., L. L. Pewe, S. M. Kaech, and J. T. Harty. 2013. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity 39: 939-948.
46. Lines, J. L., S. Hoskins, M. Hollifield, L. S. Cauley, and B. A. Garvy. 2010. The migration of T cells in response to influenza virus is altered in neonatal mice. J. Immunol. 185: 2980-2988.
47. + T-cell memory in the respiratory tract. Nat. Med. 8: 54-60.
48. Vallbracht, S., H. Unsöld, and S. Ehl. 2006. Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections. Eur. J. Immunol. 36: 1434-1442.
49. + T cells following paramyxovirus infection of the respiratory tract. J. Virol. 79: 3339-3349.
50. Claassen, E. A., P. A. van der Kant, Z. S. Rychnavska, G. M. van Bleek, A. J. Easton, and R. G. van der Most. 2005. Activation and inactivation of antiviral CD8 T cell responses during murine pneumovirus infection. J. Immunol. 175: 6597-6604.
51. Arimilli, S., E. M. Palmer, and M. A. Alexander-Miller. 2008. Loss of function in virus-specific lung effector T cells is independent of infection. J. Leukoc. Biol. 83: 564-574.
52. Arimilli, S., S. K. Sharma, R. Yammani, S. D. Reid, G. D. Parks, and M. A. Alexander-Miller. 2010. Pivotal Advance: Nonfunctional lung effectors exhibit decreased calcium mobilization associated with reduced expression of ORAI1. J. Leukoc. Biol. 87: 977-988.
53. Kremer, M., Y. Suezer, A. Volz, T. Frenz, M. Majzoub, K. M. Hanschmann, M. H. Lehmann, U. Kalinke, and G. Sutter. 2012. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog. 8: e1002557.
54. He, X. S., T. H. Holmes, K. Mahmood, G. W. Kemble, C. L. Dekker, A. M. Arvin, and H. B. Greenberg. 2008. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J. Infect. Dis. 197: 803-811.
55. Fukazawa, Y., H. Park, M. J. Cameron, F. Lefebvre, R. Lum, N. Coombes, E. Mahyari, S. I. Hagen, J. Y. Bae, M. D. Reyes, III, et al. 2012. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat. Med. 18: 1673-1681.
56. Reed, S. G., M. T. Orr, and C. B. Fox. 2013. Key roles of adjuvants in modern vaccines. Nat. Med. 19: 1597-1608.
57. Pérez, O., B. Romeu, O. Cabrera, E. González, A. Batista-Duharte, A. Labrada, R. Pérez, L. M. Reyes, W. Ramírez, S. Sifontes, et al. 2013. Adjuvants are key factors for the development of future vaccines: lessons from the finlay adjuvant platform. Front. Immunol. 4: 407.
58. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
59. Seth, R. B., L. Sun, and Z. J. Chen. 2006. Antiviral innate immunity pathways. Cell Res. 16: 141-147.
60. Mukherjee, S., and N. W. Lukacs. 2013. Innate immune responses to respiratory syncytial virus infection. Curr. Top. Microbiol. Immunol. 372: 139-154.
61. Iwasaki, A., and P. S. Pillai. 2014. Innate immunity to influenza virus infection. Nat. Rev. Immunol. 14: 315-328.
62. Caron, G., D. Duluc, I. Frémaux, P. Jeannin, C. David, H. Gascan, and Y. Delneste. 2005. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J. Immunol. 175: 1551-1557.
63. Bourke, E., D. Bosisio, J. Golay, N. Polentarutti, and A. Mantovani. 2003. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102: 956-963.
64. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
65. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdörfer, T. Giese, S. Endres, and G. Hartmann. 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168: 4531-4537.
66. Marques, J. T., and B. R. Williams. 2005. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 23: 1399-1405.
67. Mizel, S. B., and J. T. Bates. 2010. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol. 185: 5677-5682.
68. Delgado, M. F., S. Coviello, A. C. Monsalvo, G. A. Melendi, J. Z. Hernandez, J. P. Batalle, L. Diaz, A. Trento, H. Y. Chang, W. Mitzner, et al. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15: 34-41.
69. Yan, S. R., G. Qing, D. M. Byers, A. W. Stadnyk, W. Al-Hertani, and R. Bortolussi. 2004. Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear cells in response to lipopolysaccharide. Infect. Immun. 72: 1223-1229.
70. Levy, O., K. A. Zarember, R. M. Roy, C. Cywes, P. J. Godowski, and M. R. Wessels. 2004. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J. Immunol. 173: 4627-4634.
71. Dowling, D. J., Z. Tan, Z. M. Prokopowicz, C. D. Palmer, M. A. Matthews, G. N. Dietsch, R. M. Hershberg, and O. Levy. 2013. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS ONE 8: e58164.
72. Means, T. K., F. Hayashi, K. D. Smith, A. Aderem, and A. D. Luster. 2003. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J. Immunol. 170: 5165-5175.
73. McCarron, M., and D. J. Reen. 2009. Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 182: 55-62.
74. Crespo, M., D. G. Martinez, A. Cerissi, B. Rivera-Reyes, H. B. Bernstein, M. M. Lederman, S. F. Sieg, and A. A. Luciano. 2012. Neonatal T-cell maturation and homing receptor responses to Toll-like receptor ligands differ from those of adult naive T cells: relationship to prematurity. Pediatr. Res. 71: 136-143.
75. Weimer, E. T., S. E. Ervin, D. J. Wozniak, and S. B. Mizel. 2009. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 27: 6762-6769.
76. Levy, O., E. E. Suter, R. L. Miller, and M. R. Wessels. 2006. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 108: 1284-1290.
77. Levy, O., M. Coughlin, B. N. Cronstein, R. M. Roy, A. Desai, and M. R. Wessels. 2006. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J. Immunol. 177: 1956-1966.
78. Warger, T., P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. Schmitt, H. Schild, and M. P. Radsak. 2006. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550.
79. Krumbiegel, D., F. Zepp, and C. U. Meyer. 2007. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum. Immunol. 68: 813-822.
80. Randhawa, A. K., and T. R. Hawn. 2008. Toll-like receptors: their roles in bacterial recognition and respiratory infections. Expert Rev. Anti Infect. Ther. 6: 479-495.
81. Vander Veen, R. L., D. L. Harris, and K. I. Kamrud. 2012. Alphavirus replicon vaccines. Anim. Health Res. Rev. 13: 1-9.
82. Tonkin, D. R., P. Jorquera, T. Todd, C. W. Beard, R. E. Johnston, and M. Barro. 2010. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 28: 3238-3246.
83. Carroll, T. D., S. R. Matzinger, M. Barro, L. Fritts, M. B. McChesney, C. J. Miller, and R. E. Johnston. 2011. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques. Vaccine 29: 931-940.
84. Herbert, A. S., A. I. Kuehne, J. F. Barth, R. A. Ortiz, D. K. Nichols, S. E. Zak, S. W. Stonier, M. A. Muhammad, R. R. Bakken, L. I. Prugar, et al. 2013. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J. Virol. 87: 4952-4964.
85. Caley, I. J., M. R. Betts, D. M. Irlbeck, N. L. Davis, R. Swanstrom, J. A. Frelinger, and R. E. Johnston. 1997. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71: 3031-3038.
86. Widman, D. G., T. Ishikawa, L. D. Giavedoni, V. L. Hodara, Mde. L. Garza, J. A. Montalbo, A. P. Travassos Da Rosa, R. B. Tesh, J. L. Patterson, R. Carrion, Jr., et al. 2010. Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a nonhuman primate model of West Nile virus infection. Am. J. Trop. Med. Hyg. 82: 1160-1167.
87. Franchini, M., C. Abril, C. Schwerdel, C. Ruedl, M. Ackermann, and M. Suter. 2001. Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus. J. Virol. 75: 83-89.
88. Pan, C. H., C. E. Greer, D. Hauer, H. S. Legg, E. Y. Lee, M. J. Bergen, B. Lau, R. J. Adams, J. M. Polo, and D. E. Griffin. 2010. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J. Virol. 84: 3798-3807.
89. Cottalorda, A., C. Verschelde, A. Marçais, M. Tomkowiak, P. Musette, S. Uematsu, S. Akira, J. Marvel, and N. Bonnefoy-Berard. 2006. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur. J. Immunol. 36: 1684-1693.
90. Hasan, U., C. Chaffois, C. Gaillard, V. Saulnier, E. Merck, S. Tancredi, C. Guiet, F. Brière, J. Vlach, S. Lebecque, et al. 2005. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol. 174: 2942-2950.
91. Kaisho, T. 2012. Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine 30: 7652-7657.
92. Coffman, R. L., A. Sher, and R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
93. Ryan, M., L. Gothefors, J. Storsaeter, and K. H. Mills. 1997. Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice. Dev. Biol. Stand. 89: 297-305.